Trial Profile
A first in human study of ACI-12589 for Parkinson's disease
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs ACI-12589 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- 24 Feb 2021 Status changed from planning to recruiting, according to an AC Immune media release.
- 08 Feb 2021 According to an AC Immune media release, the results of this study are expected in Q3 2021. The first patient has been scanned in this study.
- 30 Mar 2020 According to an AC Immune media release, this study is expected to be initiated in Q4 2020.